Evidence map›Paper›PMID 40581051›Full record

ArticleAntiviral research2025

LAVR-289, a broad-spectrum antiviral, protects immunosuppressed Syrian hamsters against lethal adenovirus challenge.

Ann E Tollefson, Anna Cline-Smith, Vincent Roy, Luigi A Agrofoglio, Getahun Abate, Franck Gallardo, Karoly Toth

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antiviral research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ann E TollefsonSaint Louis University, School of Medicine, Department of Molecular Microbiology and Immunology, St. Louis, MO, 63110, USA.
Anna Cline-SmithSaint Louis University, School of Medicine, Department of Molecular Microbiology and Immunology, St. Louis, MO, 63110, USA.
Vincent RoyInstitute of Organic and Analytical Chemistry (ICOA UMR 7311), University of Orleans, CNRS, F-45067, Orléans, France.
Luigi A AgrofoglioInstitute of Organic and Analytical Chemistry (ICOA UMR 7311), University of Orleans, CNRS, F-45067, Orléans, France.
Getahun AbateSaint Louis University, School of Medicine, Department of Internal Medicine, St. Louis, MO, 63110, USA.
Franck GallardoNeoVirTech SAS, Toulouse, France.
Karoly TothSaint Louis University, School of Medicine, Department of Molecular Microbiology and Immunology, St. Louis, MO, 63110, USA. Electronic address: karoly.toth@health.slu.edu.

Funding

NIAID NIH HHS 75N93024F00002NIAID NIH HHS HHSN272201700041I
6 · The paper itself

Abstract

LAVR-289, a newly described acyclic nucleoside phosphonate prodrug, has previously shown in vitro efficacy against adenovirus (HAdV) species B, C, D, E, and F with EC

Indexed as

AdenoviridaeAdenoviridae InfectionsAdenoviruses, HumanAdenovirus Infections, HumanAntiviral AgentsOrganophosphonatesAnimalsCricetinaeDisease Models, AnimalFibroblastsHumansImmunocompromised HostMaleMesocricetusVirus ReplicationAntiviral AgentsOrganophosphonatesAcyclic nucleoside phosphonateAdenovirusAnimal modelAntiviralProdrug

Identifiers

PMID40581051
PMCPMC13479718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.